Literature DB >> 27294955

Relationship between vacA Types and Development of Gastroduodenal Diseases.

Tran Thi Huyen Trang1,2, Tran Thanh Binh3,4, Yoshio Yamaoka5,6.   

Abstract

The Helicobacter pylori vacuolating cytotoxin (VacA) is a secreted pore-forming toxin and a major virulence factor in the pathogenesis of H. pylori infection. While VacA is present in almost all strains, only some forms are toxigenic and pathogenic. While vacA and its genotypes are considered as markers of H. pylori-related diseases or disorders, the pathophysiological mechanisms of VacA and its genotypes remain controversial. This review outlines key findings of publications regarding vacA with emphasis on the relationship between vacA genotypes and the development of human disease.

Entities:  

Keywords:  H. pylori-mediated diseases; VacA genotypes; prolonged Helicobacter pylori infection; vacuolation

Mesh:

Substances:

Year:  2016        PMID: 27294955      PMCID: PMC4926148          DOI: 10.3390/toxins8060182

Source DB:  PubMed          Journal:  Toxins (Basel)        ISSN: 2072-6651            Impact factor:   4.546


1. VacA and Allelic Diversity of vacA

Helicobacter pylori (H. pylori) infection has been implicated in a range of disorders of the upper gastrointestinal tract and associated organs. However, virulence mechanisms responsible for H. pylori persistence and clinical outcomes remain controversial. Ongoing efforts to decipher the pathophysiology of H. pylori infection have illuminated crucially important contributions of a number of bacterial factors in H. pylori pathogenesis. The vacuolating cytotoxin (VacA) has been identified as one of the most important of these virulence factors. As an intracellular-acting protein exotoxin, VacA affects multiple cellular pathways in different host cell types and induces host cell vacuolation and cell death. Furthermore, specific vacA genotypes have also been reported to be useful for predicting risk of different clinical outcomes [1,2,3]. Although nearly all strains isolated from humans possess the vacA gene, the capacity to induce cell vacuolization differs significantly from strain to strain [4,5]. Previously, vacuolating cytotoxin phenotypes were determined based on the levels of vacA transcription or by the efficiency of VacA secretion [6]. However, subsequent studies have demonstrated that phenotypes are modulated by genetic variation within the vacA gene. The three high sequence diversity regions of the vacA closely associated with vacuolating activity and with clinical outcomes include the signal (s)-, intermediate (i)-, and middle (m)- region [5,7,8,9,10,11]. The vacA s- and the m-regions are the two main polymorphic regions and have been well-characterized as markers of H. pylori’s virulence and risk of progression to serious diseases [5,7,12,13,14]. The first polymorphic region of vacA (s-region) includes both signal peptides and is defined as a part of the apparatus to transport the mature virulent 88 kDa VacA toxin and the amino-terminal residues of p33 which is predicted as a highly hydrophobic domain of VacA. In contrast, the m-region encodes part of the carboxyl-terminal p55 subunit which has an important role in mediating VacA binding to host cells [15]. The i-region is the third polymorphic determinant and is located in the carboxyl-terminal half of p33 between the s-region and m-region [10]. The i-region appears to interact with the s and m regions and has been described as the determinant of VacA toxicity. Furthermore, the i-region has been suggested to be a better predictor of disease severity than either the s- or m-regions [10,16]. Based on the amino acid sequence differences within these regions, two or more primary variants have been described for each region: s1 and s2 for the signal region; i1, i2 and i3 for the intermediate region; and m1 and m2 for the middle region. Furthermore, the s1 and m1 genotypes have been further classified into three subtypes s1a, s1b, s1c and m1a, m1b, m1c, respectively [5,9,11,17,18,19]. Recently, two additional regions of variation were found in vacA: the deletion (d)-region, located between the i- and the m-region exhibiting either d1 genotype without the 69–81 base pair (bp) deletion or d2 genotype with the deletion; and c-region [20,21]. The last includes a deletion of 15 bp located at the 3′-end region sequences of the vacA and divided into c1 (with deletion) and c1 (without deletion) (Figure 1).
Figure 1

Sequence diversity regions of the vacA closely associated with vacuolating activity of H. pylori and clinical outcomes are localized to the signal region (SR); the intermediate region (IR) on p33 domain; the d-region (DR), middle region (MR) and c-region (CR) on p55 domain. The different types of these regions are associated with differences in vacuolation, specificity and clinical outcome. The s1, m1, i1 type have been classified as fully active VacA and are associated with a higher risk of development of GC than the s2, m2, or i2. In contrast to the s1 type, the s2 forms of VacA consistently lack detectable vacuolation activity in most in vitro assays. In comparison to the m1/i1 types, the m2/i2 types are considerably less active and are virtually nontoxic. The function of the i3 remains undefined. The d-region has been considered to be related with VacA binding to the host gastric cells and vacuolating activity, however, compelling evidence to support this is still lacking. The function of the c-region remains a mystery; however, the c1 genotype has been strongly associated with the risk of GC. The s1 and m1 genotype have been further classified into the three subtypes s1a, s1b, s1c and m1a, m1b, m1c, respectively.

2. The Association of vacA Genotypes and Cytotoxin

The most distinct effect of VacA is vacuolation of cells. After VacA internalization, internal membranous vesicles accumulate. Anion-selective channels are created in the membrane of these vesicles which facilitate the transport of chloride ions. VacA induces the accumulation of membrane permeable weak bases and finally results in osmotic swelling and vacuolation [22,23]. Even though the physiological role of vacuolation is still unclear, vacuolation occurring during H. pylori infection is thought to disrupt protein trafficking pathways to and from the plasma membrane and consequently affect a number of cellular functions [24,25,26]. vacA genotypes rather than simply the presence or absence of VacA have been identified as critical determinants of pathogenesis, Recent studies have explored the contributions of different vacA genotypes in relation to vacuolating activity as well as to H. pylori pathogenesis. vacA s1 encodes a protein which fully exhibits vacuolating activity. vacA s2 encodes a protein with a different signal peptide cleavage site, resulting in a 12-amino-acid amino-terminal extension that inhibits vacuolation [27]. Differences in the cell-binding properties of m1 and m2 VacA proteins have also been recognized. For example, the protein encoded by vacA m1 causes vacuolation in a wider range of cells than the m2-encoded protein [5,12,19,28]. Many studies have reported the genotype of vacA i-region is a marker of disease outcome; however, there has been relatively few studies comparing the activities of the proteins encoded by different types of i-region. vacA i1 shows the strongest vacuolating activity on mammalian cells and is thought to cause significantly greater gastric mucosal inflammation compared to infection with i2 containing strains [10,16]. Being phylogenetically closer to the i2 genotype, the i3 genotype is non-vacuolating and has rarely been found [11]. The combination of the vacA s-, m-, i-, region genotypes among H. pylori strains provides better differentiation of vacuolating activity between strains and clinical outcomes. Variations in the s- and m-regions gives rise to four different H. pylori genotypes; s1m1, s1m2, s2m1 and s2m2 with different abilities to induce the formation of acidic vacuoles in infected cells. In general, s1m1 strains produce a large amount of toxin and cause the greatest vacuolization of epithelial cells. In contrast, s1m2 strains may or may not induce cell vacuolation depending on the cell line; most s2m2 strains produce little or no cytotoxin. s2m1 strains are rare and non-vacuolating [6,10,18,29,30]. All s1m1i1 strains are vacuolating and all s2m2i2 are non-vacuolating. s1m2 strains containing the i1 genotype induce cell induce cellular vacuolation while those containing the i2 genotype do not. Thus, s1m1i1 and s1m2i1strains are more virulent and more likely associated with gastric cancer (GC) than the s2m2i2 and s1m2i2 strains [1,10,31]. Although the d1- and c1- genotype have been considered as biomarkers of a strong risk of GC, the contribution of the d- and c-region and their genotypes to cellular vacuolation is as yet undefined. Considering genotypes of the d- and c-region in combination with genotypes of other variant regions, d1/c1 strains are almost exclusively associated with types producing vacuolating cytotoxin (s1/m1/i1) and d2/c2 with non-vacuolating types (s2/m2/i2) [20,21]. Further studies will be required to systematically analyze the role of these regions and their genotypes in the induction of vacuolation.

3. The Relationship between vacA Polymorphism and H. pylori Persistence

After colonizing host cells, the bacteria produce toxins which can cause a broad spectrum of cellular alterations. The toxin has also been hypothesized to enable bacterial colonization by creating extensive remodeling of host cells to provide a more suitable colonization niche. Thus, toxin-producing bacteria may have a selective advantage for colonization compared with strains that do not produce a particular toxin [23]. Since all H. pylori strains possess vacA and genotype of the vacA is significantly associated with the risk of developing a clinical diseases, the secreted pore-forming toxin VacA is thought to facilitate H. pylori persistence. It has been proposed that VacA enhances the ability of H. pylori to colonize the mouse stomach [32]. However, H. pylori strains with vacA type s1 and s2 have both been able to colonize the mouse stomach without a significant difference [33]. This has been further clarified by experiments in which it was shown that the expression of the s1i1 or s1i2 genotypes significantly reduced both the proportion of successful infections and gastric colonization density in successfully infected mice compared with the expression of the s2i2 genotype [34]. Other data suggested a correlation between vacA genotype with H. pylori persistence and antimicrobial susceptibility. For example, most H. pylori isolates found to be resistant to all tested antibiotics were positive for the vacA s1a m1 genotype [35]. The contribution of the vacA genotype to persistent infection has also been related to VacA associated inhibition of the proliferation and immune response of T cells [36]. During H. pylori infection, T cells are hypo-responsive thought to be related to the activity of transforming growth factor β (TGF-β) exerting a suppressive effect on T cells. The expression levels of mucosal TGF-β1 have been demonstrated to be dependent on the vacA genotypes, with a positive correlation being reported between secreted vacA s1 or s1m1 types and increased mucosal TGF-β1 mRNA levels. Thus, the vacA s1m1 genotypes have been thought to contribute to persistent infection with H. pylori. On the other hand, the role of the active genotype s1 in H. pylori persistence has been suggested to be related to preserving the niche for H. pylori by inducing attenuation of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) system [37]. The down-regulation of the TRAIL system, in the context of an H. pylori infection, may limit apoptosis of gastric epithelial cells and destruction of tissues necessary for H. pylori to maintain its niche and survival in gastric epithelial cells. The down-regulation of the TRAIL system has been shown to be reduced in patients infected with H. pylori carrying the vacA s1 compared to those carrying the vacA s2. Prolonged H. pylori infection has been presumed to lead to saturation of cellular repair capabilities, the loss of glands, resulting in atrophic gastritis, followed by the development of intestinal metaplasia and dysplasia [38,39,40]. Thus, by facilitating H. pylori consistent colonization in the host cells, active VacA producing strains may contribute to H. pylori disease pathogenesis.

4. Role of the vacA Genotype in Gastroduodenal Diseases

H. pylori infection increase apoptosis in the gastric mucosa which may contribute to gastric diseases including peptic ulcer diseases (PUD) and GC [15,41,42,43,44]. In an effort to characterize the role of different vacA genotypes in H. pylori-associated gastroduodenal diseases, the effect of the vacA genotypes on gastric epithelial cells has been increasingly investigated. Numerous studies have provided evidence for a stronger association of disease outcomes in individuals infected with H. pylori strains possessing active vacA genotypes such as s1, m1, i1, d1 than that with less or non-active vacA types [5,14,15,18]. The prevalence of these genotypes in patients with PUD and GC is significantly greater than among those with gastritis alone [2,14,45]. The differential geographic distribution of these genotypes has also suggested the prevalence of vacA types was higher in areas where the incidence of GC is high compared to areas with a low incidence of GC [46]. An association of vacA s1 strains and enhanced gastric mucosal inflammation was found in very early studies evaluating the contribution of the vacA genotype in gastroduodenal diseases [30,47,48]. The vacA s1 allele was specified to be correlated with extensive chronic inflammation independently of the cagA status, possibly through its enhanced ability to produce the vacuolating cytotoxin [48]. The vacA s1 genotype has been associated with the higher levels of interleukin (IL)-8 in the gastric mucosa, chronic inflammation, neutrophil activity, epithelial damage; and with atrophy and intestinal metaplasia rather than the s2 genotype [16,39,49,50]. Thus, strains harboring the s1 allele have been considered to be associated with an increased risk of gastric carcinoma than infection with s2 allele containing strains. vacA m1 strains have also been associated with gastric diseases and GC compared to m2 strains. The m1 genotype has proven to be a better marker than cagA status or vacA s1 genotype for describing the difference of the incidence of GC among East Asian countries where nearly all strains are East Asian types cagA and vacA s1 [46]. However, some studies have indicated that vacA m-region typing alone is insufficient to distinguish gastroduodenal diseases or identify an increased incidence of GC [49,51]. When m-region genotypes are combined with other vacA genotypes or other virulent factors such as cagA, the contributions of the vacA genotypes to lesion progression of infected patients are more evident [52,53]. The prevalence of vacA s1m1 and s1m2 genotypes differ among intestinal GC (IGC) and diffuse GC (DGC) suggesting that these genotypes may play different roles in the pathogenesis of IGC and diffuse DGC [54]. The s1m1 genotype has been found more frequently in children with ulcers, whereas the s2/m2 genotype has been more frequent in patients with gastritis and gastroesophageal reflux disease (GERD) [55]. cagA-positive strains also correlated with severe histopathological damage and CagA is most commonly associated with the vacA s1 genotype, particularly in patients with PUD or GC [56]. Additionally, the cagA+ vacA s1 genotye is present in patients with high expression of tumor necrosis factor receptor-associated factor 1 (TRAF1), tumor necrosis factor receptor superfamily member 9 (4-1BB), or B-cell lymphoma-extra-large (Bcl-xl) [57]. The expression of TRAF1, and Bcl-xl in human gastric epithelial cells is significantly upregulated in intestinal metaplasia and gastric carcinoma patients whereas in atrophic gastritis there is low expression of these factors. Overall, it seems likely that cagA+/vacA s1m1 strains upregulate TRAF1 activation, which triggers 4-4BB mediated Bcl-xL activation, thereby exerting an antiapoptotic effect and contributing to the pathogenesis of GC [57]. Interestingly, one study reported a trend for more virulent cagA+/vacA s1m1 strains to be present in younger individuals [49], suggesting that the virulence of the infecting strain in early life may determine outcome. The contribution of genotypes of i-region to gastric diseases has been varied among epidemiology studies [10,16,58,59]. However, most studies confirm tht vacAi genotypes are better predictors of risk of GC or duodenal ulcer than other vacA alleles, cagA status, or the size of the cagA 3′ variable repeat region [2,60,61]. The strong correlation between the vacA i1 strains and PUD has been recently highlighted [21], and no significant correlation was found between genotypes of s-, m-, d- or c-region, whether independently or in combination and PUD as only the i1 type was linked to an increased risk of PUD [21]. The authors suggested that the carriage of both the i1 type and cagA further increased the risk of PUD in an Iranian population. The ability of the vacAi region to identify patients at higher risk of GC development may be an increased capacity to inhibit activation of nuclear factor of activated T cells (NFAT) and suppress IL-2 production [62]. A comparison of the ability of the i1 and i2 genotypes to cause functional alterations in Jurkat cells did not reveal differences in the capacity of the i1 and i2 forms in causing vacuolation of RK13 cells; however, i2 forms bound to Jurkat cells less avidly than the i1 forms; i2 forms had a diminished capacity to inhibit the activation of NFAT and suppress IL-2 production compared to the i1 form. Regarding the combination of 3 vacA regions (s, m, i), the authors found that only naturally occurring s1m2 strains varied in i-types with s1m1 and s2m2 strains were exclusively i1 and i2, respectively. Even though knowledge of the structure–function relationships of the vacA d region is limited, vacA d1 strains have been proposed as a new determinant of GC risk and for the potential for atrophy compared to the s-, m-, and i-regions [20,63]. Moreover, s1 strains with the d1 genotype were also considered as risk biomarkers in areas of high GC incidence in Iran [64]. Although the biologic role of the c-region in vacuole-creating activities is yet to be understood, the vacA c1 type has been strongly associated with the risk of GC [21]. Furthermore, the combination between the c1 type with vacA-m1, -i1, -d1 and cagA+ showed a further increase in susceptibility to GC; the combination of c1/i1 type showed the highest risk of GC. The vacA genotypes have been demonstrated to be better determinants of the severity of gastric damage compared to the bacterial load. Winter et al. compared vacA genotypes associated-gastric damage in infected-humans and -mice [34] and, as discussed above, compared with the less-active vacA s2i2 strains, strains producing the s1i1 and the s1i2 showed reduced colonization rates and bacterial densities. However, no significant correlation between colonization density and gastric pathology was observed. Despite colonizing poorly, the s1i1 strains consistently induced more severe and extensive inflammation and spasmolytic polypeptide expressing metaplasia (SPEM) than the s2i2 strains. The finding supported the hypothesis that the induction of inflammation and severe gastroduodenal diseases more related to VacA expression than bacterial density. This finding is in agreement with previous study which showed H. pylori genotype is more relevant than bacterial density for induction of oxidative DNA damage involved in gastric carcinogenesis [65]. In that study, density of H. pylori was not associated with the level of oxidative DNA damage whereas the more-virulent s1 and m1 strains were associated with higher levels of oxidative DNA damage than the s2 and the m2 containing strains, respectively.

5. Role of vacA Genotype in Extragastroduodenal Diseases

H. pylori-mediated diseases from outside of the gastrointestinal track such as disorder in lung or heart have attracted the attention of researchers. H. pylori infection was associated with reduced lung function that is most likely due to the effect of the bacterium on lung growth earlier in life [66]. H. pylori infection has also been associated with systemic inflammation and increased risk of cardiovascular mortality in patients with chronic obstructive pulmonary disease (COPD) [66]. Nevertheless, the attribution of H. pylori virulence including the vacA genotypes to development of these diseases remains unclear. To test the importance of H. pylori presence in the pathophysiology of upper respiratory diseases in children, a study conducted on children undergoing surgery for adenotonsillar hypertrophy reported that 98% of the sample was positive for H. pylori with predominance of the s1bm2 genotype [67]. Recently, a study demonstrated for the first time that VacA was present in human lung tissues and was more prevalent in lungs of patients with collagen vascular disease-associated interstitial pneumonia than in those of patients with idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia and cryptogenic organizing pneumonia [68]. The findings of the study suggested that induction of IL-8 and IL-6 in airway epithelial cells had a specific reaction against VacA stimulation. Consistent with this finding, another study on the specific relationship between smoking and bacterial load has noted the evidence of the association of the vacA i1 genotype with active-smoking [69]. According to a report of the Surgeon General, the cardiovascular risks were reported to be attributable to active-smoking. Therefore, the correlation of the vacA genotypes in development of diseases in H. pylori infected smokers needs to be considered in further study. These correlations remain speculative and it is still unclear whether their presence is restricted to H. pylori.

6. Conclusions

H. pylori-associated clinical outcomes relate in part to the genetic diversity among clinical H. pylori isolates. Although all H. pylori strains possess vacA, the secretion and toxicity of VacA are dissimilar among strains. These differences correlate to vacA polymorphisms. A number of recent studies have demonstrated clinical and biological differences between strains containing different vacA polymorphisms. Detailed studies of the biological activities and clinical associations related to different vacA genotypes are required for a deeper understanding of their role in H. pylori-mediated diseases and for the development of novel strategies to counter their effects.
  69 in total

1.  vacA i-region subtyping.

Authors:  Hiroaki Ogiwara; David Y Graham; Yoshio Yamaoka
Journal:  Gastroenterology       Date:  2008-02-08       Impact factor: 22.682

2.  Vacuolating cytotoxin genotypes are strong markers of gastric cancer and duodenal ulcer-associated Helicobacter pylori strains: a matched case-control study.

Authors:  Ameer A Memon; Nawfal R Hussein; Véronique Y Miendje Deyi; Alain Burette; John C Atherton
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

3.  Identification and analysis of a new vacA genotype variant of Helicobacter pylori in different patient groups in Germany.

Authors:  S Strobel; S Bereswill; P Balig; P Allgaier; H G Sonntag; M Kist
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

4.  Enhanced disease severity in Helicobacter pylori-infected mice deficient in Fas signaling.

Authors:  Nicola L Jones; Andrew S Day; Hilary Jennings; Patrick T Shannon; Esther Galindo-Mata; Philip M Sherman
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 5.  Helicobacter pylori VacA, a paradigm for toxin multifunctionality.

Authors:  Timothy L Cover; Steven R Blanke
Journal:  Nat Rev Microbiol       Date:  2005-04       Impact factor: 60.633

6.  Evaluation of Helicobacter pylori vacA genotype in Japanese patients with gastric cancer.

Authors:  T Shimoyama; T Yoshimura; T Mikami; S Fukuda; J E Crabtree; A Munakata
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

7.  Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains.

Authors:  T L Cover; M K Tummuru; P Cao; S A Thompson; M J Blaser
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

8.  Role of deletion located between the intermediate and middle regions of the Helicobacter pylori vacA gene in cases of gastroduodenal diseases.

Authors:  Hiroaki Ogiwara; Mitsushige Sugimoto; Tomoyuki Ohno; Ratha-Korn Vilaichone; Varocha Mahachai; David Y Graham; Yoshio Yamaoka
Journal:  J Clin Microbiol       Date:  2009-09-02       Impact factor: 5.948

Review 9.  Remodeling the host environment: modulation of the gastric epithelium by the Helicobacter pylori vacuolating toxin (VacA).

Authors:  Ik-Jung Kim; Steven R Blanke
Journal:  Front Cell Infect Microbiol       Date:  2012-03-27       Impact factor: 5.293

10.  A role for the vacuolating cytotoxin, VacA, in colonization and Helicobacter pylori-induced metaplasia in the stomach.

Authors:  Jody A Winter; Darren P Letley; Katherine W Cook; Joanne L Rhead; Abed A M Zaitoun; Richard J M Ingram; Karin R Amilon; Nicola J Croxall; Phillip V Kaye; Karen Robinson; John C Atherton
Journal:  J Infect Dis       Date:  2014-03-12       Impact factor: 5.226

View more
  12 in total

Review 1.  Peptic Ulcer and Gastric Cancer: Is It All in the Complex Host-Microbiome Interplay That Is Encoded in the Genomes of "Us" and "Them"?

Authors:  Angitha N Nath; R J Retnakumar; Ashik Francis; Prakash Chhetri; Namrata Thapa; Santanu Chattopadhyay
Journal:  Front Microbiol       Date:  2022-04-25       Impact factor: 6.064

Review 2.  Genetic populations and virulence factors of Helicobacter pylori.

Authors:  Evariste Tshibangu Kabamba; Vo Phuoc Tuan; Yoshio Yamaoka
Journal:  Infect Genet Evol       Date:  2018-02-19       Impact factor: 3.342

3.  Differences in amino acid frequency in CagA and VacA sequences of Helicobacter pylori distinguish gastric cancer from gastric MALT lymphoma.

Authors:  Masahiko Hashinaga; Rumiko Suzuki; Junko Akada; Takashi Matsumoto; Yasutoshi Kido; Tadayoshi Okimoto; Masaaki Kodama; Kazunari Murakami; Yoshio Yamaoka
Journal:  Gut Pathog       Date:  2016-11-08       Impact factor: 4.181

Review 4.  Current understanding and management of Helicobacter pylori infection: an updated appraisal.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  F1000Res       Date:  2018-06-11

Review 5.  Helicobacter pylori Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment.

Authors:  Jacek Baj; Alicja Forma; Monika Sitarz; Piero Portincasa; Gabriella Garruti; Danuta Krasowska; Ryszard Maciejewski
Journal:  Cells       Date:  2020-12-25       Impact factor: 6.600

6.  Study on the value of antibiotic-resistant gene detection in Helicobacter pylori in China.

Authors:  Jinfeng Dai; Jing Zhao; Liqi Mao; Yue Hu; Bin Lv
Journal:  Exp Ther Med       Date:  2022-01-18       Impact factor: 2.447

Review 7.  Helicobacter pylori Vacuolating Toxin and Gastric Cancer.

Authors:  Mark S McClain; Amber C Beckett; Timothy L Cover
Journal:  Toxins (Basel)       Date:  2017-10-12       Impact factor: 4.546

8.  Primary antibiotic resistance and its relationship with cagA and vacA genes in Helicobacter pylori isolates from Algerian patients.

Authors:  Meryem Bachir; Rachida Allem; Abedelkarim Tifrit; Meriem Medjekane; Amine El-Mokhtar Drici; Mustafa Diaf; Kara Turki Douidi
Journal:  Braz J Microbiol       Date:  2018-02-13       Impact factor: 2.476

Review 9.  Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity.

Authors:  Shamshul Ansari; Yoshio Yamaoka
Journal:  Toxins (Basel)       Date:  2019-11-19       Impact factor: 4.546

10.  Whole Genome Sequencing Reveals Virulence Potentials of Helicobacter pylori Strain KE21 Isolated from a Kenyan Patient with Gastric Signet Ring Cell Carcinoma.

Authors:  Catherine Mwangi; Stephen Njoroge; Evariste Tshibangu-Kabamba; Zahir Moloo; Allan Rajula; Smita Devani; Takashi Matsumoto; Kimang'a Nyerere; Samuel Kariuki; Gunturu Revathi; Yoshio Yamaoka
Journal:  Toxins (Basel)       Date:  2020-08-29       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.